Treatment with dl-PHPB, memantine, and donepezil, respectively, could reverse the expression of VDAC1 and cofilin 2 to near-normal levels, indicating that these two proteins may serve as candidate biomarkers for assessing therapeutic efficacy in AD. The gene discussed is CFL2; the disease is Alzheimer disease.